Search results
Results From The WOW.Com Content Network
The incidence of TA-GvHD in immunocompromised patients receiving blood transfusions is estimated to be 0.1–1.0%, and mortality around 80–90%. Mortality is higher in TA-GvHD than in GvHD associated with bone marrow transplantation , where the engrafted lymphoid cells in the bone marrow are of donor origin (in autotransplant) and therefore ...
A relationship between intra-operative blood transfusion and cancer recurrence has been observed in colorectal cancer. [64] In lung cancer intra-operative blood transfusion has been associated with earlier recurrence of cancer, worse survival rates and poorer outcomes after lung resection.
However, these types of transplants come at a cost of diminished graft-versus-tumor effect, greater risk of engraftment failure, or cancer relapse, [39] and general immunodeficiency, resulting in a patient more susceptible to viral, bacterial, and fungal infection. In a multi-center study, disease-free survival at three years was not different ...
Febrile non-hemolytic transfusion reaction (FNHTR) is the most common type of transfusion reaction. It is a benign occurrence with symptoms that include fever but not directly related with hemolysis. [1] It is caused by cytokine release from leukocytes within the donor product as a consequence of white blood cell breakdown.
A blood substitute (also called artificial blood or blood surrogate) is a substance used to mimic and fulfill some functions of biological blood. It aims to provide an alternative to blood transfusion , which is transferring blood or blood-based products from one person into another.
Often this occurs in people receiving cancer chemotherapy. [1] Preventive transfusion is often done in those with platelet levels of less than 10 x 10 9 /L. [2] In those who are bleeding transfusion is usually carried out at less than 50 x 10 9 /L. [2] Blood group matching (ABO, RhD) is typically recommended before platelets are given. [2]
Hemotherapy (/ h iː m ə ˈ θ ɛr ə p i / HEE-mə-THERR-ə-pee) or hemotherapeutics (/ h iː m ə θ ɛr ə ˈ p juː t ɪ k s / HEE-mə-THERR-ə-PEW-tiks) is the treatment of disease by the use of blood or blood products from blood donation (by others or for oneself). [1] It includes various types, such as: [citation needed] Blood ...
Peripheral blood stem cell transplantation (PBSCT), also called "Peripheral stem cell support", [1] is a method of replacing blood-forming stem cells.Stem cells can be destroyed through cancer treatments such as chemotherapy or radiation, as well as any blood-related diseases, such as leukemia, lymphoma, neuroblastoma and multiple myeloma. [2]